Risk factor
High price volatility
Profitability factor
Greatly overvalued vs peers
About
TaiMed Biologics Inc. is a biotechnology enterprise specializing in the development, manufacturing, and commercialization of pharmaceutical solutions for the treatment and prevention of infectious ailments. Its flagship product, Ibalizumab (TMB-355) Intravenous Infusion, is a marketed humanized monoclonal antibody designed to combat HIV-1 infection. Further expanding its portfolio, TaiMed is advancing other formulations of TMB-355, including an Intravenous Push version and an Intramuscular Injection, the latter currently undergoing Phase III clinical trials for HIV-1. The pipeline also features TMB-365, an anti-CD4 recombinant humanized monoclonal antibody that has concluded Phase I clinical trials for HIV, and TMB-380, identified as a neutralizing HIV-1 antibody. Established in 2007, the company maintains its headquarters in Taipei, Taiwan.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overvalued on P/FCF.